New Breast LN XRT Guidelines

[RadOncMegatron]

Advertisement - Members don't see this ad

I just saw this and wanted everyone’s thoughts on using Oncotype DX RS to determine radiation risk / benefit. Looks like the authors have it on the algorithm for determining RNI, but my understanding was that it’s too early to use for local control.

https://www.practicalradonc.org/article/S1879-8500(26)00001-9/abstract?fbclid=IwZXh0bgNhZW0CMTEAc3J0YwZhcHBfaWQPNDA5OTYyNjIzMDg1NjA5AAEeBZezW-u2lJE1iYyvLzYi4A3WpxtsEOpW4uD_Cg96PwPOZzVR6L1UWsDiWtk_aem_SEvPBXhV6F-tC-m7o7z43w

 

[madchemist89]

I wasn’t able to find the article at the link.

 

[RadOncMegatron]

I wasn’t able to find the article at the link.

I fixed the link. Title is “Lymph Node Management of Patients With Breast Cancer in the Era of Therapy De-escalation” in PRO.

 

[fiji128]

Nice review article.

 

[TheWallnerus]

In chess we sometimes say "It's a move."

It's an article. A fair number of "±"'s.

Good to see that not everyone is applying ENI as a class solution for N+ anymore. I would never say I told you so 🙂

However, just wanna check one other thing. Re: the "level 1/2" axillary RT... this is based MORE on assumption/extrapolation and not evidence/proof really, right. I don't mean it to sound accusatory, but I can't really frame the question briefly in another way.

And I agree I would use criteria from randomized trials specifically testing ENI questions for ENI; Oncotype I would not use for ENI decisions.